Improving Patient Education and Reducing Risk

Marcia L. Buck, Pharm.D., FCCP

Pediatr Pharm. 2001;7(7) 

In This Article

Formulary Update

The following actions were taken by the Pharmacy and Therapeutics Committee at their meeting on 6/22/01:

  1. Bismuth subgallate epinephrine (BSE) paste, a compounded topical hemostatic agent, was added to the Formulary for the control of bleeding after adenotonsillectomy.

  2. Tolterodine LA (Detrol LA®) was added to the Formulary for the control of overactive bladder. Oxybutynin XL (Ditropan XL®) was rejected.

  3. A request for the addition of a leuprolide acetate implant (Viadur®) was rejected because the product lacks significant advantages over the 4 month depot injection.

  4. Valganciclovir (Valcyte®) was added for the management of CMV retinitis.